384 related articles for article (PubMed ID: 20065291)
1. Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists.
Rajagopal D; Paturel C; Morel Y; Uematsu S; Akira S; Diebold SS
Blood; 2010 Mar; 115(10):1949-57. PubMed ID: 20065291
[TBL] [Abstract][Full Text] [Related]
2. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod.
Gibson SJ; Lindh JM; Riter TR; Gleason RM; Rogers LM; Fuller AE; Oesterich JL; Gorden KB; Qiu X; McKane SW; Noelle RJ; Miller RL; Kedl RM; Fitzgerald-Bocarsly P; Tomai MA; Vasilakos JP
Cell Immunol; 2002; 218(1-2):74-86. PubMed ID: 12470615
[TBL] [Abstract][Full Text] [Related]
3. TLR7 ligand augments GM-CSF-initiated antitumor immunity through activation of plasmacytoid dendritic cells.
Narusawa M; Inoue H; Sakamoto C; Matsumura Y; Takahashi A; Inoue T; Watanabe A; Miyamoto S; Miura Y; Hijikata Y; Tanaka Y; Inoue M; Takayama K; Okazaki T; Hasegawa M; Nakanishi Y; Tani K
Cancer Immunol Res; 2014 Jun; 2(6):568-80. PubMed ID: 24830413
[TBL] [Abstract][Full Text] [Related]
4. Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells.
Drobits B; Holcmann M; Amberg N; Swiecki M; Grundtner R; Hammer M; Colonna M; Sibilia M
J Clin Invest; 2012 Feb; 122(2):575-85. PubMed ID: 22251703
[TBL] [Abstract][Full Text] [Related]
5. A TLR7/8 Agonist-Including DOEPC-Based Cationic Liposome Formulation Mediates Its Adjuvanticity Through the Sustained Recruitment of Highly Activated Monocytes in a Type I IFN-Independent but NF-κB-Dependent Manner.
Auderset F; Belnoue E; Mastelic-Gavillet B; Lambert PH; Siegrist CA
Front Immunol; 2020; 11():580974. PubMed ID: 33262759
[TBL] [Abstract][Full Text] [Related]
6. Regulation of the activity of an adeno-associated virus vector cancer vaccine administered with synthetic Toll-like receptor agonists.
Triozzi PL; Aldrich W; Ponnazhagan S
Vaccine; 2010 Nov; 28(50):7837-43. PubMed ID: 20937315
[TBL] [Abstract][Full Text] [Related]
7. Inhibition and promotion of tumor growth with adeno-associated virus carcinoembryonic antigen vaccine and Toll-like receptor agonists.
Triozzi PL; Aldrich W; Ponnazhagan S
Cancer Gene Ther; 2011 Dec; 18(12):850-8. PubMed ID: 21869824
[TBL] [Abstract][Full Text] [Related]
8. The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice.
Ma F; Zhang J; Zhang J; Zhang C
Cell Mol Immunol; 2010 Sep; 7(5):381-8. PubMed ID: 20543857
[TBL] [Abstract][Full Text] [Related]
9. Selective control of type I IFN induction by the Rac activator DOCK2 during TLR-mediated plasmacytoid dendritic cell activation.
Gotoh K; Tanaka Y; Nishikimi A; Nakamura R; Yamada H; Maeda N; Ishikawa T; Hoshino K; Uruno T; Cao Q; Higashi S; Kawaguchi Y; Enjoji M; Takayanagi R; Kaisho T; Yoshikai Y; Fukui Y
J Exp Med; 2010 Apr; 207(4):721-30. PubMed ID: 20231379
[TBL] [Abstract][Full Text] [Related]
10. Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy.
Broomfield SA; van der Most RG; Prosser AC; Mahendran S; Tovey MG; Smyth MJ; Robinson BW; Currie AJ
J Immunol; 2009 May; 182(9):5217-24. PubMed ID: 19380767
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the adjuvant effect of agonists of toll-like receptor 4 and 7/8 in a vaccine against leishmaniasis in BALB/c mice.
Rostamian M; Niknam HM
Mol Immunol; 2017 Nov; 91():202-208. PubMed ID: 28963929
[TBL] [Abstract][Full Text] [Related]
12. Imiquimod enhances the potency of an exogenous BM-DC based vaccine against mouse melanoma.
Ren S; Wang Q; Zhang Y; Song Y; Dong X; Zhang W; Qin X; Liu M; Yu T
Int Immunopharmacol; 2018 Nov; 64():69-77. PubMed ID: 30149266
[TBL] [Abstract][Full Text] [Related]
13. Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses.
Loré K; Betts MR; Brenchley JM; Kuruppu J; Khojasteh S; Perfetto S; Roederer M; Seder RA; Koup RA
J Immunol; 2003 Oct; 171(8):4320-8. PubMed ID: 14530357
[TBL] [Abstract][Full Text] [Related]
14. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8.
Gorden KB; Gorski KS; Gibson SJ; Kedl RM; Kieper WC; Qiu X; Tomai MA; Alkan SS; Vasilakos JP
J Immunol; 2005 Feb; 174(3):1259-68. PubMed ID: 15661881
[TBL] [Abstract][Full Text] [Related]
15. TRAIL(+) human plasmacytoid dendritic cells kill tumor cells in vitro: mechanisms of imiquimod- and IFN-α-mediated antitumor reactivity.
Kalb ML; Glaser A; Stary G; Koszik F; Stingl G
J Immunol; 2012 Feb; 188(4):1583-91. PubMed ID: 22231699
[TBL] [Abstract][Full Text] [Related]
16. Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response.
Zhang L; Huang J; Chen X; Pan C; He Y; Su R; Guo D; Yin S; Wang S; Zhou L; Chen J; Zheng S; Qiao Y
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34452929
[TBL] [Abstract][Full Text] [Related]
17. Systemic cancer therapy with a small molecule agonist of toll-like receptor 7 can be improved by circumventing TLR tolerance.
Bourquin C; Hotz C; Noerenberg D; Voelkl A; Heidegger S; Roetzer LC; Storch B; Sandholzer N; Wurzenberger C; Anz D; Endres S
Cancer Res; 2011 Aug; 71(15):5123-33. PubMed ID: 21697281
[TBL] [Abstract][Full Text] [Related]
18. TLR7 tolerance is independent of the type I IFN pathway and leads to loss of anti-tumor efficacy in mice.
Koga-Yamakawa E; Murata M; Dovedi SJ; Wilkinson RW; Ota Y; Umehara H; Sugaru E; Hirose Y; Harada H; Jewsbury PJ; Yamamoto S; Robinson DT; Li CJ
Cancer Immunol Immunother; 2015 Oct; 64(10):1229-39. PubMed ID: 26091797
[TBL] [Abstract][Full Text] [Related]
19. Signaling through TLR7 enhances the immunosuppressive activity of murine CD4+CD25+ T regulatory cells.
Forward NA; Furlong SJ; Yang Y; Lin TJ; Hoskin DW
J Leukoc Biol; 2010 Jan; 87(1):117-25. PubMed ID: 19843574
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
